Remise en question de la thérapie par castration.

Since androgen signaling plays a pivotal role in the proliferation and metastasis of prostate cancer, androgen deprivation therapy (ADT) or castration therapy is considered the backbone of treatment for newly diagnosed metastatic prostate cancer. However, almost all men experience disease progression on ADT to a state known as metastatic castration-resistant prostate cancer (mCRPC), which continues to be driven by intratumoral androgen synthesis or androgen receptor signaling. Hence, the extragonadal ablation of androgen synthesis from pregnane precursors holds much promise. An inhibitor of cytochrome P450 17α−hydroxy/17,20-lyase (CYP17) enzymes, abiraterone acetate, has already been approved for men with mCRPC. Newer CYP17 inhibitors continue to be developed which are either more selective or have concomitant inhibitory actions on AR signaling. These include VT-464, orteronel, and galeterone. Herein, we focus on the molecular mechanism of action, efficacy, latest evidence, and clinical potential of CYP17 inhibitors in prostate cancer.

---

Parce que la signalisation des androgènes joue un rôle essentiel dans la prolifération et la métastase du cancer de la prostate, la thérapie de privation androgénique (ADT) ou la thérapie de la castration est considérée comme l'épine dorsale du traitement pour le cancer de la prostate métastatique récemment diagnostiqué. Cependant, presque tous les hommes font l'expérience de la progression de la maladie sur ADT à un état connu sous le nom métastatique cancer de la prostate résistant à la castration (CPMRC), qui continue d'être alimentée par la synthèse des androgènes intratumorale ou de signalisation du récepteur des androgènes. Par conséquent, l'ablation extragonadique de la synthèse des androgènes à partir de précurseurs prégnane est très prometteur. Un inhibiteur d'enzymes du cytochrome P450 17α-hydroxy / 17,20-lyase (CYP17), l'acétate d'abiratérone, a déjà été approuvé pour les hommes avec CPMRC. Les inhibiteurs de CYP17 récents continuent d'être développés qui sont soit plus sélectif ou ont une action inhibitrice concomitants sur la signalisation AR. Ceux-ci comprennent VT-464, orteronel et galeterone.

(Jun. 1, 2008) — For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone -- the hormone that fuels prostate-cancer growth -- via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow.

Pour les dernières 70 ans, le traitement du cancer avancé métastasé de la a été la privation d'androgène: C'est la suppression de testostérone, l'hormone qui nourrit la progression du cancer de la prostate, par la castration physique ou chimique. Même si une telle théapie achète du temps pour le patient, ça ne guérit pas le cancer et celui-ci devient inévitablement résistant à la privation d'androgène et continue à croitre.


A team of researchers led by Peter Nelson, M.D., and Elahe (pronounced EL-ah-hay) Mostaghel, M.D., Ph.D., of Fred Hutchinson Cancer

Research Center; and R. Bruce Montgomery, M.D., and Paul Lange, M.D., of the University of Washington School of Medicine, in collaboration with other colleagues at UW and Oregon Health Sciences University, has uncovered what may be the key to understanding how prostate tumors eventually become resistant to androgen-deprivation therapy.

une équipe de chercheur a découvert comment le cancer devient résistant à la thérapie.

"We found that despite the suppression of circulating androgen levels to very low or castrate levels, metastatic prostate tumors are themselves able to maintain significant levels of testosterone, which fuels the growth of the cancer," said Mostaghel, a clinical-research associate in Nelson's laboratory, which is based in the Human Biology Division of the Hutchinson Center.

Les tumeurs métastasique sont capable de garder des niveaux significatifs de testostérone ce qui nourrit la progression du cancer.

The researchers found that testosterone levels were four times higher in metastatic tumors from castrate men (collected immediately after death via rapid autopsy) than in benign and cancerous prostate tissue in men with normal circulating androgen levels (collected at the time of prostate surgery).

Les chercheurs ont découverts que les niveaux de testostérone sont 4 fois plus haut dans les tumeurs des hommes castrés que dans les tissus cancéreus des hommes sans privation d'androgène.

This finding, reported in the June 1 issue of Cancer Research, could lead to the development of better drugs to treat metastatic disease -- cancer that has spread beyond the prostate to distant sites throughout the body, such as bone, lymph nodes and internal organs.

Cette découverte pourrait conduire à de meilleurs médicaments pour traiter la maladie métastasique qui a progressé dans le corps aux os ou lymphes ou aux organes internes.

"So far we've targeted systemic, or circulating, androgens in men with advanced prostate cancer," Mostaghel said. "What these findings suggest is that we really need to target the metastatic prostate-tumor tissue itself as the source of tumor androgens."

Ce que nous avons découvert suggère que nous aurions besoin de cibler les tissus métastasés eux-mêmes comme source de tumeurs androgènes.

In addition to measuring androgen levels in distant tumor sites, the researchers analyzed gene-expression patterns in the metastatic tissue to confirm the presence of genetic pathways that control testosterone production. The researchers indeed found within the metastatic tissue the genetic transcripts necessary for making the proteins that produce testosterone and other androgen hormones.

"We not only found that metastatic-tumor tissues have high enough androgen levels within them to support continued growth of the tumor cells, but also a critically important reason behind why those androgens are there -- the discovery that the gene pathways for synthesizing androgens from cholesterol appear to be present in the distant tumor sites. This finding will allow us to start honing in on the specific source of those androgens and how we can eliminate them," Mostaghel said. "As we develop new drug targets, we will need to focus on enzymes that seem to be active in the tumor tissue itself. This offers a new way of looking at hormone suppression. In addition to systemic suppression, it suggests we also need to target hormone suppression much more specifically, inside the tumor itself." Doing so could improve treatment for patients with all stages of prostate cancer, she said, from men with metastatic disease to men with high-risk, localized tumors in which there is concern that small amounts of cancer may have escaped the prostate.

Mostaghel and colleagues feel the most promising drug targets will be inhibitors of CYP17 enzymes, which disrupt the conversion of progesterone to testosterone precursors, as well as inhibitors of enzymes that perform subsequent steps in testosterone production: AKR1C3 and 17BHSD3.

Mostaghel et ses collègues pensent que le médicament le plus prometteur sera l'inhibiteur des enzymes CYP17 qui interrompt la communication entre les précurseurs de la progesterone et la testostérone ainsi que les inhibiteurs des enzymes qui font l'étape subséquente soit AKR1C3 et le 17BHSD3.  

For the study, the researchers examined soft-tissue prostate-cancer metastases obtained from eight medically or surgically castrated men via the University of Washington rapid-autopsy program, one of a handful of such programs in the nation. For control purposes, the researchers also examined benign and cancerous prostate tissue from eight men who underwent radical prostatectomy for early-stage, localized prostate cancer, and prostate tissue from two men whose prostates were removed for reasons unrelated to prostate cancer.

The researchers also examined metastatic human prostate-cancer cells, obtained from androgen-deprived men, which had been engrafted and allowed to grow in both castrated and non-castrated mice, a process called xenografting.

Androgen levels in the xenograft tumors in the castrated mice, which had no circulating androgen, were actually higher than in the xenograft tumors in the mice that had not been castrated. The researchers found a particularly striking difference in levels of DHT. "We found DHT levels to be twice as high in the castrated mice," Mostaghel said. "That tells us that the tumor is making testosterone and hanging on to it somehow and is further evidence that metastatic tissue has the capacity to make its own testosterone."

Each year, approximately 200,000 U.S. men are diagnosed with prostate cancer. While the majority of cases are early-stage, localized disease -- due in large part to the widespread use of PSA, or prostate-specific antigen screening -- an estimated 50 percent of patients diagnosed and treated for clinically localized prostate cancer will progress to more advanced disease, which kills an estimated 30,000 American men annually.

Funding sources for this research included the National Institutes of Health, the Department of Defense and the Prostate Cancer Foundation.